Original Research

Diagnostic Accuracy of L-FABP-to-Creatinine Ratio (LCR) for Prediction of Kidney Damage in Type-2 DM Patients Taking Albumin-to-Creatinine Ratio (ACR) as Gold Standard

DOI https://doi.org/10.70302/jpsim.v5i4.2465
Received: 02 Jul 2024 Accepted: 14 Nov 2024 Published Online: 09 Dec 2024

Abstract

Objective

To determine the diagnostic accuracy of LCR for the prediction of kidney damage in Type-2 Diabetes Mellitus
patients keeping ACR as gold standard.

Methods

It was a descriptive study conducted in diabetic center of Lahore General Hospital on 70 Type 2 diabetics, 35 to
55 years old having negative spot urine dipstick test for albumin. After informed consent, urine samples were collected for
measurements of ACR and LCR. Patients with cardiovascular disease, hypertension, liver disease, pregnancy, anemia or
any other chronic disease were excluded. ACR 30-300 mg/g was labeled as having Diabetic Nephropathy (DN). Data was
analyzed in SPSS-27.

Results

The mean ± SD age, BMI, duration of DM of participants was 49.6 ± 4.7 years, 29.3 ± 3.0 kg/m2, 6.2 ± 1 years
respectively. Using 5.5 µg/g cut off value for LCR, the sensitivity, specificity, positive predictive value, negative
predictive value, Youden's index and overall diagnostic accuracy was 85.5%, 93.3%, 0.98, 0.6, 0.78 and 0.87 respectively.
Area under curve (AUC) was 0.81.

Conclusion

L-FABP has overall good diagnostic accuracy to predict kidney damage in Type-2 diabetics.

Keywords
Albumin Creatinine Liver type FattyAcid Binding Protein Creatinine Type 2 DM Kidney damage

How to Cite This Article

Sultan E, Sultan A, Dar R, Sultan U, Ghani MH, Kousar N. Diagnostic Accuracy of L-FABP-to-Creatinine Ratio (LCR) for Prediction of Kidney Damage in Type-2 DM Patients Taking Albumin-to-Creatinine Ratio (ACR) as Gold Standard. J Pak Soc Intern Med. 2024;5(4):690–693. doi:10.70302/jpsim.v5i4.2465

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. Valencia WM., Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. Bmj. 2017 Jan 17;356.
  2. Fawaz SS., Mahmoud AA., Touny EA., Mahmoud MS. Role of kidney injury molecule 1 and nephrin as biomarkers for diagnosis of nephropathy in type 2 diabetes mellitus. J. curr. med. res. pract. 2022 Oct 1;7(4):304-9.
  3. Kare PK., Garg M. Assessment of Urinary Liver-Type Fatty Acid Binding Protein (LFABP) Levels in Type 2 Diabetes Mellitus Patients with Nephropathy. J clin diagn Res. 2019 Jan 1;13(1) ):21-24..
  4. Tang S. and Sharma K. Pathogenesis, clinical manifestations, and natural history of diabetic kidney disease. In: Feehally J., Floege J., Tonelli M., Johnson RJ. 2019. Comprehensive Clinical Nephrology, 6th ed. Edinburgh: Elsevier Inc: 357-373.
  5. Kopel J., Pena-Hernandez C., Nugent K. Evolving spectrum of diabetic nephropathy. World journal of diabetes. 2019 May 5;10(5):269-279.
  6. Yamanouchi M., Furuichi K., Hoshino J., Ubara Y., Wada T. Nonproteinuric diabetic kidney disease. Clin Exp Nephrol. 2020 Jul;24:573-81.
  7. Thi TN., Gia BN., Le Thi HL., Thi TN., Thanh HP. Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem 2020 Jan 1;39(2):224-230.
  8. Nishimura H., Ishii J., Takahashi H., Kitagawa F., Kawai H., Muramatsu T., et al. Urinary Liver-Type Fatty Acid-Binding Protein is More Useful Than Neutrophil Gelatinase-Associated Lipocalin for Predicting Acute Kidney Injury. Circulation. 2019 Nov 19;140(Suppl_1):A14296.
  9. Hartomuljono A., Salahuddin A., Amin H., Gaus S., Nurdin H., Muchtar F., et al. The Role of Urine Liver Fatty Acid Binding Protein in Early Detection of Acute Kidney Injury in Septic Patient. Egyptian Journal of Critical Care Medicine. 2021 Dec 1;8(4):114-7.
  10. Sato E., Kamijo-Ikemori A., Oikawa T., Okuda A., Sugaya T., Kimura K., et al. Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis. Renal Replacement Therapy. 2017 Dec;3:1-10.
  11. Suzuki G., Ichibayashi R., Yamamoto S., Serizawa H., Nakamichi Y., Watanabe M., Honda M. Urinary liver-type fatty acid-binding protein variation as a predictive value of short-term mortality in intensive care unit patients. Renal Failure. 2021 Jan 1; 43(1):1041-8.
  12. Lu YC., Chang CC., Wang CP., Hung WC., Tsai IT., Tang WH., et al. Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Int J Med Sci. 2020;17(2):182.
  13. Azeem S., Khan U., Liaquat A. The increasing rate of diabetes in Pakistan: A silent killer. Ann Med Surg (Lond). 2022 Jul 1;79. [on line] https://pubmed.ncbi.nlm.nih.gov/35860160/
  14. Lin YC., Chang YH., Yang SY., Wu KD., Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formosan Med Assoc. 2018 Aug 1; 117(8): 662-75.
  15. Chen Y., Lee K., Ni Z., He JC. Diabetic kidney disease: challenges, advances, and opportunities. Kidney diseases. 2020 Jul 17;6(4):215-25.
  16. Ballermann BJ., Nyström J., Haraldsson B. The glomerular endothelium restricts albumin filtration. Front Med. 2021 Nov 29;8:766689.
  17. Pugliese G., Penno G., Natali A., Barutta F., Di Paolo S., Reboldi G., et al. Society ID. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutrition, Metabolism and Cardiovascular Diseases. 2019 Nov 1;29 (11):1127-50.
  18. Hamasaki H. Urinary liver‐type fatty acid‐binding protein is a predictor of mortality in individuals with type 2 diabetes. Diabetic Medicine. 2021 Jun; 38(6):e14527.
  19. Panduru NM. Urinary biomarkers for the prediction of diabetic nephropathy, cardiovascular disease and mortality in individuals with type 1 diabetes. 2021.Academic Dissertation, University of Helsinki, Finland. pp-27.
  20. Rabie AA., Ragheb AT., Serag SA., Mohammed WF. Liver-type fatty acid-binding protein as an early biomarker of nephropathy in type-2 diabetes. Menoufia Med J. 2020; 33(3): 760-5.
  21. Xia M., Liu K., Feng J., Zheng Z., Xie X. Prevalence and risk factors of type 2 diabetes and prediabetes among 53,288 middle-aged and elderly adults in China: A cross-sectional study. Diabetes Metab Syndr Obes. 2021 May 3:1975-85.
  22. Lee DY., Kim J., Park S., Park SY., Yu JH., Seo JA., et al.. Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study. J. Clin. Med. 2021 Dec 18;10(24):5948.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2024 Journal of Pakistan Society of Internal Medicine.